Reuters logo
9 个月前
BRIEF-Gtx's Enobosarm has been well tolerated among patients
2016年11月28日 / 下午12点42分 / 9 个月前

BRIEF-Gtx's Enobosarm has been well tolerated among patients

Nov 28 (Reuters) - Gtx Inc

* Enobosarm meets pre-specified primary efficacy endpoint in ongoing phase 2 clinical trial in ER+/AR+ breast cancer

* Enobosarm has been well tolerated among patients treated to date in 9 mg dose cohort with majority of adverse events being either grade 1 or 2

* Gtx says plans to report top-line clinical results from these 22 evaluable patients from 9 mg dose cohort in December 2016

* Gtx says expects to report top-line clinical results from full study by middle of 2017, following completion of clinical trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below